{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T05:09:15Z","timestamp":1780549755876,"version":"3.54.1"},"reference-count":65,"publisher":"SAGE Publications","issue":"3","license":[{"start":{"date-parts":[[2025,7,7]],"date-time":"2025-07-07T00:00:00Z","timestamp":1751846400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2025,7,7]],"date-time":"2025-07-07T00:00:00Z","timestamp":1751846400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of Neuromuscular Diseases"],"published-print":{"date-parts":[[2026,5]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction:<\/jats:title>\n                    <jats:p>Limb-Girdle Muscular Dystrophies (LGMDs) are heterogeneous inherited disorders with no cure, including 29 recessive (LGMDR) and 5 dominant forms (LGMDD), characterized by proximal muscle weakness. Finding a cure for LGMD is difficult due to the their slow evolution for which comprehensive data collection through registries, network, and natural history studies is pivotal.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>We conducted a review following PRISMA guidelines searching in PubMed, Scopus, and Web of Science for articles published between 2000\u20132025, focusing on LGMD registries, networks, and natural history studies. We included observational studies, cohort designs, and registry-based studies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Among 443 records, 38 studies were included, 10 registries, 4 networks, and 17 natural history studies respectively. Registries varied in scope, with many focused on specific LGMD subtypes. Natural history studies were predominantly subtype-specific, poorly linked to registries. Only 12 studies were connected to registries or networks, and most performed in Europe and North America.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion:<\/jats:title>\n                    <jats:p>Registries, networks, and natural history studies showed considerable design variability, leading to challenges with data interoperability and underscoring the need for standardization. Despite regional coverage, low-income countries are underrepresented in the data. The limited linkage between natural history studies and registries presents a missed opportunity to leverage well-characterized cohorts. Many registries and networks remain unpublished, limiting available data for global research.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Registries are crucial, benefiting patients, clinicians, researchers, and industries. The scarcity of natural history studies hinders the development of centralized datasets. Standardizing registry design, improving data interoperability, and enhancing patient diversity are critical to boost LGMD research.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/22143602251355316","type":"journal-article","created":{"date-parts":[[2025,7,8]],"date-time":"2025-07-08T03:00:26Z","timestamp":1751943626000},"page":"507-524","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":1,"title":["Review: Limb-girdle muscular dystrophies (LGMDs) existing registries and natural history studies: Where do we stand?"],"prefix":"10.1177","volume":"13","author":[{"given":"Elena","family":"Faedo","sequence":"first","affiliation":[{"name":"Reference Center for Neuromuscular Disorders, APHP Henri Mondor University Hospital, France"},{"name":"Department of Neurosciences, Rehabilitation, Ophthalmology, Genetic and Maternal and Infantile Sciences (DINOGMI), University of Genoa, Genoa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iman","family":"Tahiri","sequence":"additional","affiliation":[{"name":"Reference Center for Neuromuscular Disorders, APHP Henri Mondor University Hospital, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"Alimi","sequence":"additional","affiliation":[{"name":"Reference Center for Neuromuscular Disorders, APHP Henri Mondor University Hospital, France"},{"name":"Institut Universitaire de Kin\u00e9sith\u00e9rapie, Facult\u00e9 de Sant\u00e9, Universit\u00e9 Paris Est, Fontainebleau, Ile-de-France, France"},{"name":"Atamyo Therapeutics, Evry, Ile-de-France, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hussein","family":"Shoaito","sequence":"additional","affiliation":[{"name":"Reference Center for Neuromuscular Disorders, APHP Henri Mondor University Hospital, France"},{"name":"Atamyo Therapeutics, Evry, Ile-de-France, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianmarco","family":"Severa","sequence":"additional","affiliation":[{"name":"Reference Center for Neuromuscular Disorders, APHP Henri Mondor University Hospital, France"},{"name":"University Paris Est Cr\u00e9teil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Olivier","sequence":"additional","affiliation":[{"name":"Atamyo Therapeutics, Evry, Ile-de-France, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephane","family":"Degove","sequence":"additional","affiliation":[{"name":"Atamyo Therapeutics, Evry, Ile-de-France, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Richard","sequence":"additional","affiliation":[{"name":"G\u00e9n\u00e9thon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edoardo","family":"Malfatti","sequence":"additional","affiliation":[{"name":"Reference Center for Neuromuscular Disorders, APHP Henri Mondor University Hospital, France"},{"name":"University Paris Est Cr\u00e9teil"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2025,7,7]]},"reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/77.2.169"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1212\/CON.0000000000001178"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1002\/mus.26077"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1051\/medsci\/2020244"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awae046"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.nmd.2018.05.007"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12883-024-03588-1"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.3233\/JND-200538"},{"key":"e_1_3_3_10_2","article-title":"Using data from patient registries to answer important research questions","volume":"50","author":"Rached S","year":"2024","unstructured":"Rached S, Patino CM, Ferreira J. Using data from patient registries to answer important research questions. J Bras Pneumol 2024; 50: e20240216.","journal-title":"J Bras Pneumol"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-023-02719-0"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.15386\/cjmed-1015"},{"key":"e_1_3_3_13_2","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page MJ","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Br Med J 2021; 372: n71.","journal-title":"Br Med J"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13643-016-0384-4"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12913-016-1477-4"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.3233\/JND-221551"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1002\/acn3.52276"},{"key":"e_1_3_3_18_2","article-title":"P.184 treat NMD LGMD global registry network development","volume":"31","author":"Segovia S","year":"2021","unstructured":"Segovia S, Ambrosini A, Campbell C, et al. P.184 treat NMD LGMD global registry network development. Neuromuscul Disord 2021; 31: S105.","journal-title":"Neuromuscul Disord"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.3233\/JND-170240"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1007\/s13760-014-0320-0"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1093\/pch\/pxx125"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.nmd.2016.06.051"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.nmd.2014.06.327"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1002\/mus.25192"},{"key":"e_1_3_3_25_2","first-page":"4941","article-title":"Clinical and genetic features of calpainopathies in Saudi Arabia \u2013 a descriptive cross-sectional study","volume":"25","author":"Alharbi N","year":"2021","unstructured":"Alharbi N, Shosha E, Murad H, et al. Clinical and genetic features of calpainopathies in Saudi Arabia \u2013 a descriptive cross-sectional study. Eur Rev Med Pharmacol Sci 2021; 25: 4941\u20134952.","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.nmd.2024.07.563"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.1002\/humu.22015"},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.1002\/acn3.51042"},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.nmd.2024.07.576"},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.1051\/myolog\/202225008"},{"key":"e_1_3_3_31_2","doi-asserted-by":"publisher","DOI":"10.1097\/CND.0b013e318163c5ba"},{"key":"e_1_3_3_32_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0090377"},{"key":"e_1_3_3_33_2","doi-asserted-by":"publisher","DOI":"10.1002\/acn3.287"},{"key":"e_1_3_3_34_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.nmd.2019.06.249"},{"key":"e_1_3_3_35_2","doi-asserted-by":"publisher","DOI":"10.1002\/acn3.774"},{"key":"e_1_3_3_36_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-021-01950-x"},{"key":"e_1_3_3_37_2","article-title":"Prospective natural history study in 24 adult patients with LGMDR12 over 2 years of follow-up: quantitative MRI and clinical outcome measures","volume":"99","author":"De Wel B","unstructured":"De Wel B, Huysmans L, Peeters R, et al. Prospective natural history study in 24 adult patients with LGMDR12 over 2 years of follow-up: quantitative MRI and clinical outcome measures. Neurology [Internet] 2022 [cit\u00e9 4 mars 2025]; 99. Disponible sur: https:\/\/www.neurology.org\/doi\/10.1212\/WNL.0000000000200708.","journal-title":"Neurology [Internet]"},{"key":"e_1_3_3_38_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.nmd.2022.07.311"},{"key":"e_1_3_3_39_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0321463"},{"key":"e_1_3_3_40_2","doi-asserted-by":"publisher","DOI":"10.1002\/jcsm.12987"},{"key":"e_1_3_3_41_2","doi-asserted-by":"publisher","DOI":"10.1002\/acn3.51709"},{"key":"e_1_3_3_42_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.nmd.2022.11.005"},{"key":"e_1_3_3_43_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.nmd.2023.07.214"},{"key":"e_1_3_3_44_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10048-022-00707-3"},{"key":"e_1_3_3_45_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.nmd.2023.07.193"},{"key":"e_1_3_3_46_2","first-page":"221436022513392","article-title":"A prospective observational study assessing the functional disease progression of LGMDR4, betasarcoglycan-related limb girdle muscular dystrophy","author":"Iammarino MA","year":"2025","unstructured":"Iammarino MA, Reash NF, Shannon K, et al. A prospective observational study assessing the functional disease progression of LGMDR4, betasarcoglycan-related limb girdle muscular dystrophy. J Neuromuscul Dis 2025: 22143602251339219.","journal-title":"J Neuromuscul Dis"},{"key":"e_1_3_3_47_2","article-title":"Clinical trial readiness in limb girdle muscular dystrophy R1 (LGMDR1): A GRASP Consortium Study","author":"Hunn SM","unstructured":"Hunn SM, Alfano LN, Jones A, et al. Clinical trial readiness in limb girdle muscular dystrophy R1 (LGMDR1): A GRASP Consortium Study. Ann Clin Transl Neurol [Internet] [cit\u00e9 26 mai 2025]; n\/a(n\/a). Disponible sur: https:\/\/onlinelibrary.wiley.com\/doi\/abs\/10.1002\/acn3.70049.","journal-title":"Ann Clin Transl Neurol [Internet]"},{"key":"e_1_3_3_48_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.nmd.2016.06.052"},{"key":"e_1_3_3_49_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10633-022-09909-4"},{"key":"e_1_3_3_50_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.nmd.2024.07.277"},{"key":"e_1_3_3_51_2","unstructured":"Sarepta Therapeutics Inc. Journey: A Global Multicenter Longitudinal Study of the Natural History of Subjects With Limb Girdle Muscular Dystrophy (LGMD) Type 2E (LGMD2E\/R4) Type 2D (LGMD2D\/R3) Type 2C (LGMD2C\/R5) and Type 2A (LGMD2A\/R1) [Internet]. clinicaltrials.gov; 2024 oct [cit\u00e9 14 avr 2025]. Report No.: NCT04475926. Disponible sur: https:\/\/clinicaltrials.gov\/study\/NCT04475926"},{"key":"e_1_3_3_52_2","unstructured":"Mathews K. Clinical Trial Readiness for the Dystroglycanopathies [Internet]. clinicaltrials.gov; 2024 avr [cit\u00e9 14 avr 2025]. Report No.: NCT00313677. Disponible sur: https:\/\/clinicaltrials.gov\/study\/NCT00313677"},{"key":"e_1_3_3_53_2","unstructured":"ML Bio Solutions Inc. Biomarker Development in LGMD2i [Internet]. clinicaltrials.gov; 2023 mars [cit\u00e9 14 avr 2025]. Report No.: NCT04202627. Disponible sur: https:\/\/clinicaltrials.gov\/study\/NCT04202627"},{"key":"e_1_3_3_54_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12883-020-01774-5"},{"key":"e_1_3_3_55_2","unstructured":"Sarepta Therapeutics Inc. Journey: A Global Multicenter Longitudinal Study of the Natural History of Subjects With Limb Girdle Muscular Dystrophy (LGMD) Type 2E (LGMD2E\/R4) Type 2D (LGMD2D\/R3) Type 2C (LGMD2C\/R5) and Type 2A (LGMD2A\/R1) [Internet]. clinicaltrials.gov; 2024 oct [cit\u00e9 15 avr 2025]. Report No.: NCT04475926. Disponible sur: https:\/\/clinicaltrials.gov\/study\/NCT04475926"},{"key":"e_1_3_3_56_2","unstructured":"Assistance Publique \u2013 H\u00f4pitaux de Paris. Evolution of the Functional and Muscular State and Quality of Life of Patients With Limb-girdle Muscular Dystrophy 2A: CALNATHIS Prospective Cohort Study [Internet]. clinicaltrials.gov; 2024 avr [cit\u00e9 15 avr 2025]. Report No.: NCT06390566. Disponible sur: https:\/\/clinicaltrials.gov\/study\/NCT06390566"},{"key":"e_1_3_3_57_2","unstructured":"Virginia Commonwealth University. Long-Term Development of Muscular Dystrophy Outcome Assessments (GRASP-01-005) [Internet]. clinicaltrials.gov; 2024 oct [cit\u00e9 15 avr 2025]. Report No.: NCT05989620. Disponible sur: https:\/\/clinicaltrials.gov\/study\/NCT05989620"},{"key":"e_1_3_3_58_2","unstructured":"IRCCS San Camillo Venezia Italy. Retrospective Analysis of Clinical and Biochemical Features for the Identification of Dominant Inheritance of Calpainopathies [Internet]. clinicaltrials.gov; 2023 juill [cit\u00e9 15 avr 2025]. Report No.: NCT05956132. Disponible sur: https:\/\/clinicaltrials.gov\/study\/NCT05956132"},{"key":"e_1_3_3_59_2","unstructured":"Alfano L. Natural History of Disease Progression in Individuals With Limb Girdle Muscular Dystrophy Type 2A and Type 2E [Internet]. clinicaltrials.gov; 2025 f\u00e9vr [cit\u00e9 15 avr 2025]. Report No.: NCT03488784. Disponible sur: https:\/\/clinicaltrials.gov\/study\/NCT03488784"},{"key":"e_1_3_3_60_2","unstructured":"Stemmerik MPG. Fast Troponin as a Biomarker to Assess Exercise-induced Muscle Damage in Muscle Diseases [Internet]. clinicaltrials.gov; 2022 oct [cit\u00e9 15 avr 2025]. Report No.: NCT04349566. Disponible sur: https:\/\/clinicaltrials.gov\/study\/NCT04349566"},{"key":"e_1_3_3_61_2","unstructured":"Virginia Commonwealth University. GRASP-01-003: Trial Readiness and Endpoint Assessment in LGMD R1 [Internet]. clinicaltrials.gov; 2025 mars [cit\u00e9 15 avr 2025]. Report No.: NCT05618080. Disponible sur: https:\/\/clinicaltrials.gov\/study\/NCT05618080"},{"key":"e_1_3_3_62_2","unstructured":"Cooperative International Neuromuscular Research Group. Evaluation of Limb-Girdle Muscular Dystrophy [Internet]. clinicaltrials.gov; 2014 mars [cit\u00e9 15 avr 2025]. Report No.: NCT00893334. Disponible sur: https:\/\/clinicaltrials.gov\/study\/NCT00893334"},{"key":"e_1_3_3_63_2","unstructured":"Zhao C. A Multicenter Phenotype-Genotype Analysis of Limb Girdle Muscular Dystrophy Patients in China [Internet]. clinicaltrials.gov; 2023 oct [cit\u00e9 15 avr 2025]. Report No.: NCT04989751. Disponible sur: https:\/\/clinicaltrials.gov\/study\/NCT04989751"},{"key":"e_1_3_3_64_2","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-319-67144-4_5"},{"key":"e_1_3_3_65_2","doi-asserted-by":"crossref","unstructured":"Liu J Barrett JS Leonardi ET et al. Natural history and real-world data in rare diseases: applications limitations and future perspectives. J Clin Pharmacol [Internet] 2022 d\u00e9c [cit\u00e9 23 juin 2025]; 62. Disponible sur: https:\/\/accp1.onlinelibrary.wiley.com\/doi\/10.1002\/jcph.2134 64","DOI":"10.1002\/jcph.2134"},{"key":"e_1_3_3_66_2","doi-asserted-by":"publisher","DOI":"10.5582\/irdr.2025.01030"}],"container-title":["Journal of Neuromuscular Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/22143602251355316","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/22143602251355316","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/22143602251355316","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T04:58:21Z","timestamp":1780549101000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/22143602251355316"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,7]]},"references-count":65,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["10.1177\/22143602251355316"],"URL":"https:\/\/doi.org\/10.1177\/22143602251355316","relation":{},"ISSN":["2214-3599","2214-3602"],"issn-type":[{"value":"2214-3599","type":"print"},{"value":"2214-3602","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,7]]}}}